Single-channel sequencing device and sequencing method
Through the combination of self-luminescence system and luciferase, the problem of optical signal excitation dependence in single-channel DNA sequencing technology is solved, and low-cost and accurate DNA sequencing is achieved, which is suitable for clinical and large-scale applications.
Patent Information
- Application Number
- CN202410524599.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2019-05-15
- Publication Date
- 2024-11-12
AI Technical Summary
The existing single-channel DNA sequencing technology requires external light sources and additional design filtration due to the excitation of optical signals, resulting in high sequencing costs and large device size, which limits its promotion in clinical and large-scale applications.
The self-luminescence system is adopted to achieve self-luminescence detection of four bases through the specific binding of luciferase and labeled nucleotides, avoiding dependence on excitation light sources and reducing the manufacturing cost and volume of the sequencing device.
It realizes a low-cost and lightweight DNA sequencing device, improves sequencing accuracy and portability, and is suitable for clinical and large-scale applications.
Smart Images

Figure CN118931711A_ABST
Abstract
Description
[0001] The present invention is a divisional application of the parent case with application number 201980095781.8, the application date of which is May 15, 2019, and the name of the invention is “A single-channel sequencing method based on spontaneous luminescence”. Technical Field
[0002] The present invention relates to the field of nucleic acid sequencing. In particular, the present invention provides a single-channel sequencing method based on self-luminescence, in which the self-luminescence signal is used to distinguish the sequential incorporation of different nucleotides, thereby realizing the determination of polynucleotide sequences. Background Art
[0003] DNA sequencing technology includes the first generation of DNA sequencing technology represented by Sanger sequencing and the second generation of DNA sequencing technology represented by Illumina Hiseq2500, Roche 454, ABI Solid, BGISEQ-500, etc. In 1977, Sanger invented the dideoxy terminal termination sequencing method, which became the representative of the first generation of sequencing technology. In 2001, the draft of the human genome was completed based on the first generation of sequencing technology. The Sanger sequencing method has the characteristics of simple experimental operation, intuitive and accurate results, and short experimental cycle. It is widely used in clinical gene mutation detection and genotyping fields that require high timeliness of test results. However, the disadvantages of the Sanger sequencing method are low throughput and high cost, which limits its application in large-scale gene sequencing. In order to overcome the shortcomings of the Sanger sequencing method, the second generation of sequencing technology came into being. Compared with the first generation of DNA sequencing technology, the second generation of DNA sequencing technology has the characteristics of large sequencing throughput, low cost, high degree of automation and single molecule sequencing. Taking the sequencing technology of HiSeq2500V2 as an example, one experimental process can generate 10-200G bases of data, and the average sequencing cost per base is less than 1 / 1000 of the sequencing cost of Sanger sequencing, and the sequencing results obtained can be directly processed and analyzed by computer. Therefore, the second-generation DNA sequencing technology is very suitable for large-scale sequencing.
[0004] The second generation DNA sequencing technologies currently developed mainly involve sequencing by ligation (SBL) technology and sequencing by synthesis (SBS) technology. Typical examples of these sequencing technologies include SOLiD sequencing developed by Applied Biosystems, combined probe anchor ligation (cPAL) independently developed by Complete Genomics and combined probe anchor synthesis (cPAS) developed by BGI, Illumina sequencing developed by Illumina and Solexa technology, etc. In these sequencing methods, Illumina and Compact Genomics use a method of detecting light signals. In order to achieve the identification and distinction of four bases (A, T / U, C and G), four fluorescent dyes are usually used to mark these four bases respectively. In this case, in order to read the fluorescent signals carried by each base, the sequencing device must be equipped with at least two monochromatic excitation light sources and at least two cameras, which results in the high manufacturing cost and huge volume of the sequencing device.
[0005] In the past 10 years, the second-generation gene sequencing technology has gradually grown from an emerging technology to a mainstream sequencing method, and has gradually become an important detection tool in the clinical field, playing an increasingly important role in the prevention and control of infectious diseases, diagnosis of genetic diseases, non-invasive prenatal screening and other fields. In order to further expand the sequencing market and make sequencers more popular, the development of low-cost miniaturized sequencers has gradually become a development trend in the sequencing field. As a classic method of second-generation sequencing technology, the three sequencing methods based on four channels, two channels and single channels have their own advantages, but compared with the three, single-channel sequencing has gradually become a development trend in the sequencing field with its advantages of fewer consumables, lower cost, and easier to achieve instrument miniaturization and portability. At present, the products based on single-color channels on the market mainly include ion torrent series sequencers, 454 sequencers and Illumina's latest Iseq100.
[0006] Among the current single-channel sequencing technologies, the ion torrent series of instruments have limited their scope of use due to the high error rate of polymer structure sequencing. Similarly, Roche's 454 instrument has gradually withdrawn from the sequencing market due to its low sequencing accuracy and high sequencing costs. Illumia's Iseq100 is based on monochrome fluorescence technology and semiconductor technology, which realizes a miniaturized sequencer and maintains a high sequencing quality. However, because its optical signal is excited by a laser, the instrument is equipped with an additional laser, which increases the size of the instrument. In addition, in order to avoid the background value generated by the excitation light, the semiconductor chip needs to be specially processed to filter out the background output of the excitation light. This processing will result in high costs and increase the sequencing cost.
[0007] Therefore, there is a need in the art for a low-cost sequencing method that does not require excitation from an external light source and does not require additional design to filter the background generated by the laser light source. SUMMARY OF THE INVENTION
[0009] In order to solve the above technical problems, the inventors of the present application have developed a new sequencing method, which uses the signal of the self-luminescent system to distinguish the four bases of A, (T / U), C and G. Therefore, the luminescent signal used to implement the sequencing method of the present invention is derived from bioluminescence or chemiluminescence, so there is no need to configure an additional laser, and there is no need to adopt an additional design to filter the background generated by the laser light source, thereby reducing the sequencing cost. The sequencing device used for the sequencing method of the present invention can even be conveniently carried around for instant / on-site detection. In addition, the 3' terminal hydroxyl group of the deoxyribonucleotide used in the sequencing method of the present invention is modified and blocked, and during the sequencing process, only one deoxyribonucleotide can be synthesized in each reaction, ensuring that only one deoxyribonucleotide is combined in each reaction, thereby improving the accuracy of sequencing.
[0010] In one aspect, the present invention provides a method for sequencing a nucleic acid molecule, comprising the following steps:
[0011] (1) providing a nucleic acid molecule to be sequenced connected to a support, or connecting the nucleic acid molecule to be sequenced to a support;
[0012] (2) adding a primer for initiating nucleotide polymerization reaction, a polymerase for carrying out nucleotide polymerization reaction, and four compounds to form a reaction system containing a solution phase and a solid phase; wherein the four compounds are derivatives of nucleotides A, (T / U), C, and G, respectively, and have base complementary pairing capabilities; and the hydroxyl group (-OH) at the 3' position of the ribose or deoxyribose of the four compounds is protected by a protecting group; and,
[0013] The first compound is linked to a first molecular label,
[0014] The second compound is linked to a second molecular label,
[0015] The third compound is connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and another part of the third compound is connected to the second molecular marker,
[0016] The fourth compound had no molecular marker attached;
[0017] (3) annealing the primer to the nucleic acid molecule to be sequenced, wherein the primer serves as the initial growing nucleic acid chain and together with the nucleic acid molecule to be sequenced forms a duplex connected to the support;
[0018] (4) performing nucleotide polymerization using a polymerase under conditions that allow the polymerase to perform nucleotide polymerization, thereby incorporating one of the four compounds into the 3' end of the growing nucleic acid chain;
[0019] (5) contacting the duplex in the previous step with two different luciferases and performing a binding reaction, wherein the two luciferases can specifically bind to the first molecular marker and the second molecular marker, respectively, and then causing the luciferases to undergo a fluorescence reaction in the presence of a substrate, and detecting the emitted fluorescence signal;
[0020] (6) removing molecular labels of individual nucleotides;
[0021] (7) Optionally repeat steps (3)-(6) or (3)-(5) one or more times to obtain sequence information of the nucleic acid molecule.
[0022] In an embodiment of the present invention, the self-luminous detection of the nucleotide to be sequenced is achieved by connecting luciferase to nucleotide derivatives, thereby eliminating the need for an additional excitation light source. In a specific embodiment, the connection between luciferase and nucleotide is achieved by the specific binding of a marker on a luciferase to a corresponding marker on a nucleotide derivative. In a specific embodiment, the first nucleotide is connected to the first luciferase, the second nucleotide is connected to the second luciferase, the third nucleotide is connected to the first luciferase and the second luciferase, and the fourth nucleotide is not connected to any luciferase. Then, the corresponding substrates of the two luciferases are introduced to detect the luminescent signals of the four bases; when the substrate of the first luciferase is introduced, the first nucleotide and the third nucleotide emit light, and when the substrate of the second luciferase is introduced, the second nucleotide and the third nucleotide emit light, so that the bases can be identified according to the luminescence of the four nucleotides.
[0023] Therefore, in an exemplary embodiment, the method of the present invention for sequencing a nucleic acid molecule comprises the following steps:
[0024] (1) providing a nucleic acid molecule to be sequenced connected to a support, or connecting the nucleic acid molecule to be sequenced to a support;
[0025] (2) adding a primer for initiating nucleotide polymerization reaction, a polymerase for carrying out nucleotide polymerization reaction, and four compounds to form a reaction system containing a solution phase and a solid phase; wherein the four compounds are derivatives of nucleotides A, (T / U), C, and G, respectively, and have base complementary pairing capabilities; and the hydroxyl group (-OH) at the 3' position of the ribose or deoxyribose of the four compounds is protected by a protecting group; and,
[0026] The first compound is linked to a first molecular label,
[0027] The second compound is linked to a second molecular label,
[0028] The third compound is connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and another part of the third compound is connected to the second molecular marker,
[0029] The fourth compound had no molecular marker attached;
[0030] (3) annealing the primer to the nucleic acid molecule to be sequenced, wherein the primer serves as the initial growing nucleic acid chain and together with the nucleic acid molecule to be sequenced forms a duplex connected to the support;
[0031] (4) performing nucleotide polymerization using a polymerase under conditions that allow the polymerase to perform nucleotide polymerization, thereby incorporating one of the four compounds into the 3' end of the growing nucleic acid chain;
[0032] (5) removing the solution phase of the reaction system in the previous step, retaining the duplex connected to the support, and adding two different luciferases to perform a binding reaction, wherein the two luciferases can specifically bind to the first molecular marker and the second molecular marker, respectively;
[0033] (6) removing unbound luciferase with elution buffer;
[0034] (7) adding a substrate of the first luciferase and detecting a fluorescence signal at the same time;
[0035] (8) removing the solution from the previous reaction;
[0036] (9) adding a second luciferase substrate and detecting the fluorescence signal at the same time;
[0037] (10) removing the solution from the previous reaction;
[0038] (11) removing the molecular label and 3' protecting group of each nucleotide;
[0039] (12) optionally removing the solution from the previous reaction;
[0040] (13) Optionally repeat steps (3)-(12) to obtain sequence information of the nucleic acid molecule.
[0041] In a specific embodiment, the connection between the two luciferases and the nucleotides can also be performed separately, for example, a first luciferase labeled with a first label can be added first, so that it reacts with the nucleotide labeled with a first molecule, and then an elution buffer is used to remove the unbound first luciferase, and a substrate of the first luciferase is added, and the fluorescence signal is detected at the same time; then a second luciferase labeled with a second label is added, so that it reacts with the nucleotide labeled with a second molecule, and then an elution buffer is used to remove the unbound second luciferase, and a substrate of the second luciferase is added, and the fluorescence signal is detected at the same time. Specifically, the present invention provides a method for sequencing a nucleic acid molecule, which comprises the following steps:
[0042] (1) providing a nucleic acid molecule to be sequenced connected to a support, or connecting the nucleic acid molecule to be sequenced to a support;
[0043] (2) adding a primer for initiating nucleotide polymerization reaction, a polymerase for carrying out nucleotide polymerization reaction, and four compounds to form a reaction system containing a solution phase and a solid phase; wherein the four compounds are derivatives of nucleotides A, (T / U), C, and G, respectively, and have base complementary pairing capabilities; and the hydroxyl group (-OH) at the 3' position of the ribose or deoxyribose of the four compounds is protected by a protecting group; and,
[0044] The first compound is linked to a first molecular label,
[0045] The second compound is linked to a second molecular label,
[0046] The third compound is connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and another part of the third compound is connected to the second molecular marker,
[0047] The fourth compound had no molecular marker attached;
[0048] (3) annealing the primer to the nucleic acid molecule to be sequenced, wherein the primer serves as the initial growing nucleic acid chain and together with the nucleic acid molecule to be sequenced forms a duplex connected to the support;
[0049] (4) performing nucleotide polymerization using a polymerase under conditions that allow the polymerase to perform nucleotide polymerization, thereby incorporating one of the four compounds into the 3' end of the growing nucleic acid chain;
[0050] (5) removing the solution phase of the reaction system in the previous step, retaining the duplex connected to the support, and adding a first luciferase to perform a binding reaction, wherein the first luciferase can specifically bind to the first molecular marker;
[0051] (6) removing unbound first luciferase with an elution buffer;
[0052] (7) adding a substrate of the first luciferase and detecting a fluorescence signal at the same time;
[0053] (8) removing the solution from the previous reaction;
[0054] (9) adding a second luciferase to perform a binding reaction, wherein the second luciferase can specifically bind to the second molecular marker;
[0055] (10) removing unbound second luciferase with elution buffer;
[0056] (11) adding a second luciferase substrate and detecting the fluorescence signal at the same time;
[0057] (12) removing the solution from the previous reaction;
[0058] (13) optionally removing the molecular label and 3' protecting group of each nucleotide;
[0059] (14) Optionally repeat steps (3)-(13) or (3)-(11) one or more times to obtain sequence information of the nucleic acid molecule.
[0060] In a specific embodiment, the two luciferases may be the same, and they can specifically bind to the first molecular marker and the second molecular marker, respectively, that is, only one luciferase and substrate are used, and the connection between the first labeled first luciferase and the second labeled second luciferase and the nucleotide is performed separately. For example, the first labeled first luciferase can be added first, so that it reacts with the nucleotide labeled with the first molecule, and then the unbound first luciferase is removed with an elution buffer, and the substrate of the luciferase is added, and the fluorescent signal is detected at the same time; then the second labeled second luciferase is added, so that it reacts with the nucleotide labeled with the second molecule, and then the unbound second luciferase is removed with an elution buffer, and the substrate of the luciferase is added, and the fluorescent signal is detected at the same time. Specifically, the present invention provides a method for sequencing a nucleic acid molecule, which comprises the following steps:
[0061] (1) providing a nucleic acid molecule to be sequenced connected to a support, or connecting the nucleic acid molecule to be sequenced to a support;
[0062] (2) adding a primer for initiating nucleotide polymerization reaction, a polymerase for carrying out nucleotide polymerization reaction, and four compounds to form a reaction system containing a solution phase and a solid phase; wherein the four compounds are derivatives of nucleotides A, (T / U), C, and G, respectively, and have base complementary pairing capabilities; and the hydroxyl group (-OH) at the 3' position of the ribose or deoxyribose of the four compounds is protected by a protecting group; and,
[0063] The first compound is linked to a first molecular label,
[0064] The second compound is linked to a second molecular label,
[0065] The third compound is connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and another part of the third compound is connected to the second molecular marker,
[0066] The fourth compound had no molecular marker attached;
[0067] (3) annealing the primer to the nucleic acid molecule to be sequenced, wherein the primer serves as the initial growing nucleic acid chain and together with the nucleic acid molecule to be sequenced forms a duplex connected to the support;
[0068] (4) performing nucleotide polymerization using a polymerase under conditions that allow the polymerase to perform nucleotide polymerization, thereby incorporating one of the four compounds into the 3' end of the growing nucleic acid chain;
[0069] (5) removing the solution phase of the reaction system in the previous step, retaining the duplex connected to the support, and adding a first luciferase to perform a binding reaction, wherein the first luciferase can specifically bind to the first molecular marker;
[0070] (6) removing unbound first luciferase with an elution buffer;
[0071] (7) adding luciferase substrate and detecting the fluorescence signal;
[0072] (8) removing the solution from the previous reaction;
[0073] (9) adding a reagent that denatures luciferase;
[0074] (10) removing the solution from the previous reaction;
[0075] (11) adding a second luciferase to perform a binding reaction, wherein the second luciferase can specifically bind to the second molecular marker;
[0076] (12) removing unbound second luciferase with elution buffer;
[0077] (13) adding a luciferase substrate and detecting the fluorescence signal;
[0078] (14) optionally removing the solution from the previous reaction;
[0079] (15) optionally removing the molecular label and 3' protecting group of each nucleotide;
[0080] (16) Optionally repeat steps (3)-(15) or (3)-(13) one or more times to obtain sequence information of the nucleic acid molecule.
[0081] In another aspect, the present invention also relates to a kit for sequencing a polynucleotide, comprising:
[0082] (a) four compounds, wherein the four compounds are derivatives of nucleotides A, (T / U), C and G, respectively, and have base complementary pairing ability; and the hydroxyl group (-OH) at the 3' position of the ribose or deoxyribose of the four compounds is protected by a protecting group; and,
[0083] The first compound is linked to a first molecular label,
[0084] The second compound is linked to a second molecular label,
[0085] The third compound is connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and another part of the third compound is connected to the second molecular marker,
[0086] The fourth compound has no molecular marker attached; and
[0087] (b) Two luciferases, the two luciferases can specifically bind to the first molecular marker and the second molecular marker respectively, and the two luciferases can be the same or different.
[0088] In certain preferred embodiments, the kit of the present invention further comprises: reagents and / or devices for extracting nucleic acid molecules from a sample; reagents for pre-treating nucleic acid molecules; a support for connecting the nucleic acid molecules to be sequenced; reagents for connecting the nucleic acid molecules to be sequenced to the support (e.g., covalently or non-covalently); primers for initiating nucleotide polymerization reactions; a polymerase for performing nucleotide polymerization reactions; one or more buffer solutions; one or more washing solutions; or any combination thereof. DETAILED DESCRIPTION OF THE INVENTION
[0090] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. All patents, applications and other publications mentioned herein are incorporated herein by reference in their entirety. If the definitions set forth herein conflict or are inconsistent with the definitions described in the patents, applications and other publications incorporated herein by reference, the definitions set forth herein shall prevail.
[0091] As used herein, the term "polynucleotide" refers to deoxyribonucleic acid (DNA), ribonucleic acid (RNA) or its analog. Polynucleotides can be single-stranded, double-stranded or contain both single-stranded and double-stranded sequences. Polynucleotide molecules can be derived from double-stranded DNA (dsDNA) forms (e.g., genomic DNA, PCR and amplification products, etc.), or can be derived from DNA (ssDNA) or RNA in single-stranded form and it can be converted into dsDNA forms, and vice versa. The accurate sequence of polynucleotide molecules can be known or unknown. The following are illustrative examples of polynucleotides: gene or gene fragment (e.g., probe, primer, EST or SAGE tag), genomic DNA, genomic DNA fragment, exon, intron, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozyme, cDNA, recombinant polynucleotides, synthetic polynucleotides, branched polynucleotides, plasmids, vectors, DNA separated by any sequence, RNA separated by any sequence, nucleic acid probes, primers or amplification copies of any of the above sequences.
[0092] Polynucleotides may include nucleotides or nucleotide analogs. Nucleotides generally contain a sugar (such as ribose or deoxyribose), a base, and at least one phosphate group. Nucleotides may be abasic (i.e., lack a base). Nucleotides include deoxyribonucleotides, modified deoxyribonucleotides, ribonucleotides, modified ribonucleotides, peptide nucleotides, modified peptide nucleotides, modified phosphate sugar backbone nucleotides, and mixtures thereof. Examples of nucleotides include, for example, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), thymidine monophosphate (TMP), thymidine diphosphate (TDP), thymidine triphosphate (TTP), cytidylic acid (CMP), cytidylic acid diphosphate (CDP), cytidylic acid triphosphate (CTP), guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), deoxyadenosine monophosphate (dAMP), Deoxyadenosine diphosphate (dADP), deoxyadenosine triphosphate (dATP), deoxythymidine monophosphate (dTMP), deoxythymidine diphosphate (dTDP), deoxythymidine triphosphate (dTTP), deoxycytidine diphosphate (dCDP), deoxycytidine triphosphate (dCTP), deoxyguanosine monophosphate (dGMP), deoxyguanosine diphosphate (dGDP), deoxyguanosine triphosphate (dGTP), deoxyuridine monophosphate (dUMP), deoxyuridine diphosphate (dUDP) and deoxyuridine triphosphate (dUTP). Nucleotide analogs comprising modified bases can also be used in the methods described herein. Exemplary modified bases that can be included in polynucleotides, whether having a natural backbone or an analogous structure, include, for example, inosine, xathanine, hypoxathanine, isocytosine, isoguanine, 2-aminopurine, 5-methylcytosine, 5-hydroxymethylcytosine, 2-aminoadenine, 6-methyladenine, 6-methylguanine, 2-propylguanine, 2-propyladenine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 15-halouracil, 15-halocytosine, 5 ... -propynyluracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-uracil, 4-thiouracil, 8-haloadenine or guanine, 8-aminoadenine or guanine, 8-thioadenine or guanine, 8-sulfanyladenine or guanine, 8-hydroxyadenine or guanine, 5-halogen-substituted uracil or cytosine, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, etc. As is known in the art, certain nucleotide analogs cannot be incorporated into polynucleotides, for example, nucleotide analogs such as adenosine 5'-phosphosulfate.
[0093] Generally speaking, nucleotides include nucleotides A, C, G, T or U. As used herein, the term "nucleotide A" refers to a nucleotide containing adenine (A) or a modification or analog thereof, such as ATP, dATP. "Nucleotide G" refers to a nucleotide containing guanine (G) or a modification or analog thereof, such as GTP, dGTP. "Nucleotide C" refers to a nucleotide containing cytosine (C) or a modification or analog thereof, such as CTP, dCTP. "Nucleotide T" refers to a nucleotide containing thymine (T) or a modification or analog thereof, such as TTP, dTTP. "Nucleotide U" refers to a nucleotide containing uracil (U) or a modification or analog thereof, such as UTP, dUTP.
[0094] Nucleotide labeling
[0095] The present invention relates to labeling nucleotides with different labels alone or in combination, so that different luciferases can be connected to nucleotides. As used herein, the molecular label used to label nucleotides and the label specifically bound thereto can be any molecular pairing that can specifically bind to each other. The specific binding between the pairing members realizes the connection between the nucleotide and the luciferase. Exemplary pairing members include, but are not limited to: (a) haptens or antigenic compounds combined with corresponding antibodies or their binding parts or fragments, such as digoxin-digoxin antibodies, N3G-N3G antibodies, FITC-FITC antibodies; (b) nucleic acid aptamers and proteins; (c) non-immune binding pairs (e.g., biotin-avidin, biotin-streptavidin, biotin-neutravidin); (d) hormone-hormone binding protein; (e) receptor-receptor agonist or antagonist; (f) lectin-carbohydrate; (g) enzyme-enzyme cofactor; (h) enzyme-enzyme inhibitor; and (i) complementary oligonucleotides or polynucleotide pairs capable of forming nucleic acid duplexes.
[0096] In a specific embodiment, the first molecular marker and the second molecular marker are small molecule markers selected from biotin, digoxin, N3G or FITC. Two luciferases can specifically bind to the first molecular marker and the second molecular marker, respectively. For example, in a specific embodiment, the first molecular marker is biotin, then the first luciferase can be a luciferase labeled with streptavidin; the second molecular marker is digoxin, then the second luciferase can be a luciferase different from the first luciferase labeled with digoxin antibody, and the second luciferase can also be a luciferase labeled with digoxin antibody and the same as the first luciferase. The luciferase source includes but is not limited to firefly, gaussia, Renilla and other organisms. For example, the luciferase labeled with streptavidin can be SA-Gluc:Streptavidin-Gaussia princeps luciferase of Adivity. The luciferase labeled with digoxin antibody can be digoxin antibody-Gluc or digoxin antibody-Nluc.
[0097] As used herein, the expression "a first compound is connected to a first molecular marker" means that all first compounds are connected to the first molecular marker, or part of the first compounds are connected to the first molecular marker but the rest of the first compounds are not connected to the molecular marker. Similarly, the expression "a second compound is connected to a second molecular marker" means that all second compounds are connected to the second molecular marker, or part of the second compounds are connected to the second molecular marker but the rest of the second compounds are not connected to the molecular marker. The expression "a third compound is connected to a first molecular marker and a second molecular marker" means that all third compounds are connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and the second molecular marker but the rest of the third compound is not connected to the molecular marker.
[0098] Polynucleotide Sequencing
[0099] Preferably, the nucleotides of the present invention connected with different luciferases are suitable for synthesis sequencing. As used herein, synthesis sequencing is a variety of synthesis sequencing methods well known in the art. Basically, synthesis sequencing involves first hybridizing the nucleic acid molecule to be sequenced with a sequencing primer, and then polymerizing the nucleotides connected with different luciferases as described herein at the 3' end of the sequencing primer using the nucleic acid molecule to be sequenced as a template in the presence of a polymerase. After polymerization, the nucleotides are identified by detecting the fluorescent signal emitted by the luciferase. After removing the luciferase from the labeled nucleotide, the next polymerization sequencing cycle is performed.
[0100] The method for determining the target polynucleotide sequence can be carried out by denaturing the target polynucleotide sequence, contacting the target polynucleotide with different nucleotides respectively to form the complement of the target nucleotide, and detecting the incorporation of the nucleotide. The method utilizes polymerization, so that the polymerase extends the complementary chain by incorporating the correct nucleotide complementary to the target. The polymerization reaction also requires special primers to initiate polymerization.
[0101] For each round of reaction, the incorporation of the nucleotide is carried out by a polymerase, and the incorporation event is subsequently determined. There are many different polymerases, and it is easy for a person of ordinary skill in the art to determine the most suitable polymerase. Preferred enzymes include DNA polymerase I, Klenow fragment, DNA polymerase III, T4 or T7 DNA polymerase, Taq polymerase or vent polymerase. Polymerases engineered to have specific properties can also be used.
[0102] The sequencing method is preferably performed on target polynucleotides arranged on a solid support. A plurality of target polynucleotides may be immobilized on the solid support via a linker molecule, or may be attached to particles such as microspheres, which may also be attached to a solid support material.
[0103] The polynucleotide can be connected to the solid support by a variety of methods, including the use of biotin-streptavidin interaction. Methods for fixing polynucleotides on solid supports are well known in the art, and include lithographic techniques and spotting each polynucleotide on a specific position of a solid support. Suitable solid supports are well known in the art, and include glass slides and beads, ceramic and silicon surfaces and plastic materials. The support is generally a plane, although microbeads (microspheres) can also be used, and the latter can also be connected to other solid supports by known methods. The microspheres can have any suitable size, and their diameter is generally 10-100 nanometers. In a preferred embodiment, the polynucleotide is directly connected to a plane, preferably to a flat glass surface. The connection is preferably carried out in the form of a covalent bond. The array used is preferably a single molecule array, which includes polynucleotides located in a unique optically resolvable region, such as described in International Application No. WO00 / 06770.
[0104] The necessary conditions for polymerization are well known to those skilled in the art. In order to carry out the polymerase reaction, it is usually necessary to first anneal the primer sequence to the target polynucleotide, which is recognized by the polymerase and serves as a starting point for the subsequent extension of the complementary chain. The primer sequence can be added as an independent component relative to the target polynucleotide. In addition, the primer and the target polynucleotide can be part of a single-stranded molecule, respectively, and an intramolecular duplex, i.e., a hairpin loop structure, is formed by the primer portion and a portion of the target. The structure can be fixed to the solid support at any site of the molecule. Other conditions necessary for carrying out the polymerase reaction are well known to those skilled in the art, and these conditions include temperature, pH, and buffer composition.
[0105] Subsequently, the labeled nucleotides of the invention are contacted with the target polynucleotide to enable polymerization. The nucleotides may be added sequentially, ie, each type of nucleotide (A, C, G or T / U) is added separately, or simultaneously.
[0106] The polymerization step is allowed to proceed for a time sufficient to incorporate one nucleotide.
[0107] Unincorporated nucleotides are then removed, for example, by removing the solution phase of the reaction from the previous step, leaving the duplex attached to the support.
[0108] Subsequently, two luciferases containing different luciferases can be added to carry out a binding reaction, and the two luciferases can specifically bind to the molecular markers used to mark nucleotides, thereby realizing the connection of luciferases with the nucleotides incorporated. Then, the identification of the nucleotides incorporated is realized by adding the substrate of the corresponding luciferase and detecting the fluorescent signal. Two luciferases containing the same luciferase can also be added to carry out a binding reaction, and the luciferases can specifically bind to the molecular markers used to mark nucleotides, thereby realizing the connection of luciferases with the nucleotides incorporated. Then, the identification of the nucleotides incorporated is realized by adding the substrate of the corresponding luciferase and detecting the fluorescent signal.
[0109] In a specific embodiment, four deoxyribonucleotide analogs are respectively labeled with different small molecule markers biotin (abbreviated as B) and digoxigenin (abbreviated as D), for example, nucleotide A is labeled with B, nucleotide C is labeled with B and D, nucleotide T is labeled with D, and nucleotide G is not labeled. The 3' terminal hydroxyl groups of the above four deoxyribonucleotide analogs labeled with different small molecules are all blocked to ensure that only one deoxyribonucleotide is bound in each sequencing reaction. During the sequencing reaction, the four labeled deoxyribonucleotide analogs and sequencing polymerase mixture are first introduced. Under the action of the polymerase, according to the principle of base complementary pairing, one deoxyribonucleotide analog is incorporated into the 3' end of the growing nucleic acid chain. By removing the solution phase of the reaction system in the previous step and retaining the duplex connected to the support, the unbound deoxyribonucleotide analog can be removed. Then, two luciferases containing different luciferases are added, the first luciferase is labeled with streptavidin, and it binds to nucleotide A or nucleotide C labeled with small molecule B, and the second luciferase is labeled with digoxigenin antibody, and it binds to nucleotide C or nucleotide T labeled with small molecule D. After removing the unbound luciferase using elution buffer, the substrate of the first luciferase is added, the nucleotide connected to the first luciferase emits light, and the detector is used to detect the signal; the substrate of the second luciferase is added, the nucleotide connected to the second luciferase emits light, and the detector is used to detect the signal, thereby obtaining the luminescence conditions shown in the table below, and the base recognition can be performed.
[0110]
[0111] In a specific embodiment, the connection of two luciferases containing different luciferases to the labeled nucleotides and the signal detection can be performed separately. First, add the first luciferase, which is labeled with streptavidin and binds to the nucleotide A or nucleotide C labeled with the small molecule B. After removing the unbound first luciferase with the elution buffer, add the substrate of the first luciferase, the nucleotide connected with the first luciferase emits light, and the detector is used to detect the signal. After removing the reaction solution, add the second luciferase labeled with digoxigenin antibody, which binds to the nucleotide C or nucleotide T labeled with the small molecule D, then remove the unbound second luciferase with the elution buffer, add the substrate of the second luciferase, the base connected with the second luciferase emits light, and the detector is used to detect the signal, thereby obtaining the luminescence shown in the above table, and the base can be identified.
[0112] In another specific embodiment, the connection of two luciferases containing the same luciferase to the labeled nucleotide and the signal detection are performed separately. First, add the first luciferase, which is labeled with streptavidin and binds to the nucleotide A or nucleotide C labeled with the small molecule B. After removing the unbound first luciferase with the elution buffer, add the substrate of the luciferase, the nucleotide connected with the first luciferase emits light, and the detector is used to detect the signal. Then add the reagent that denatures the first luciferase, remove the reaction solution, add the second luciferase labeled with the digoxigenin antibody, which binds to the nucleotide C or nucleotide T labeled with the small molecule D, then remove the unbound second luciferase with the elution buffer, add the substrate of the luciferase, the base connected with the second luciferase emits light, and the detector is used to detect the signal, thereby obtaining the luminescence shown in the above table, and the base can be identified.
[0113] Detection of fluorescence signals
[0114] The means of detecting the fluorescent signal are well known in the art. For example, it can be achieved by a device that detects the wavelength of the fluorescence. Such devices are well known in the art. For example, such a device can be a confocal scanning microscope, which scans the surface of the solid support with a laser to image the fluorophore directly bound to the sequenced nucleic acid molecule. In addition, each signal generated can be observed, for example, with a sensitive 2-D detector, such as a charge coupled detector (CCD). Other techniques such as scanning near-field optical microscopy (SNOM) can also be used, for example.
[0115] Removal of markers
[0116] After detection, the label on the nucleotide can be removed using appropriate conditions.
[0117] In specific embodiments, the labeled nucleotides of the invention also have a 3' protecting group. In some embodiments of the invention, the protecting group and the label are usually two different groups on the 3' blocked labeled nucleotide, but in other embodiments, the protecting group and the label can also be the same group.
[0118] As used herein, the term "blocking group" means such a group, which prevents the polymerase (which incorporates the nucleotide containing the group into the polynucleotide chain being synthesized) from continuing to catalyze the incorporation of another nucleotide after the nucleotide containing the group is incorporated into the polynucleotide chain being synthesized. Such a blocking group is also referred to as a 3'-OH blocking group in this article. The nucleotide comprising such a blocking group is also referred to as the nucleotide of 3' blocking in this article. The blocking group can be any suitable group that can be added to the nucleotide, as long as the blocking group can prevent other nucleotide molecules from being added into the polynucleotide chain and is easy to remove from the sugar part of the nucleotide without destroying the polynucleotide chain. In addition, the nucleotide modified by the blocking group needs to tolerate polymerase or other suitable enzymes for incorporating the modified nucleotide into the polynucleotide chain. Therefore, the ideal blocking group shows long-term stability, can be efficiently incorporated by polymerase, prevents the secondary incorporation of nucleotide or further incorporation, and can be preferably removed under aqueous conditions without destroying the mild conditions of the polynucleotide structure.
[0119] The prior art has described a variety of protecting groups that meet the above description. For example, WO 91 / 06678 discloses that 3'-OH protecting groups include esters and ethers, -F, -NH2, -OCH3, -N3, -OPO3, -NHCOCH3, 2-nitrophenyl carbonate, 2,4-sulfonyl dinitro and tetrahydrofuran ether. Metzker et al. (Nucleic Acids Research, 22 (20): 4259-4267, 1994) disclose the synthesis and use of eight 3'-modified 2-deoxyribonucleoside 5'-triphosphates (3'-modified dNTPs). WO2002 / 029003 describes the use of allyl protecting groups to cap the 3'-OH group on the growing DNA chain in a polymerase reaction. Preferably, various protecting groups reported in International Application Publications WO2014139596 and WO2004 / 018497 can be used, including for example Figure 1 A and those 3' hydroxy protecting groups (ie protecting groups) defined in the claims, and for example those protecting groups exemplified in Figures 3 and 4 of WO2004 / 018497 and those protecting groups defined in the claims. The above references are all incorporated herein by reference in their entirety.
[0120] Those skilled in the art will understand how to attach a suitable blocking group to the ribose ring to block interaction with the 3'-OH. The blocking group may be attached directly to the 3' position, or may be attached to the 2' position (where the blocking group has sufficient size or charge to block interaction at the 3' position). Additionally, the blocking group may be attached to both the 3' and 2' positions and may be cleaved to expose the 3'-OH group.
[0121] After successfully incorporating the 3' blocked nucleotide into the growing nucleic acid chain, the sequencing protocol requires the removal of the protecting group to generate an available 3'-OH site for continuous chain synthesis. As used herein, the reagents that can remove the protecting group from the modified nucleotide depend to a large extent on the protecting group used. For example, the removal of the ester protecting group from the 3' hydroxyl functional group is usually achieved by alkaline hydrolysis. The ease of removing the protecting group varies greatly; generally, the greater the electronegativity of the substituent on the carbonyl carbon, the greater the ease of removal. For example, the highly electronegative trifluoroacetic acid group can be rapidly cleaved from the 3' hydroxyl in methanol at pH 7 (Cramer et al., 1963), so it is unstable during polymerization at this pH. The phenoxyacetic acid ester group cleaves in less than 1 minute, but requires significantly higher pH, such as with NH- / methanol (Reese and Steward, 1968). A variety of hydroxyl protecting groups can be selectively cut using chemical methods other than alkaline hydrolysis. 2,4-Dinitrophenylthio groups can be rapidly cleaved by treatment with nucleophiles such as thiophenol and thiosulfate (Letsinger et al., 1964). Allyl ethers are cleaved by treatment with Hg(II) in acetone / water (Gigg and Warren, 1968). Tetrahydrothiopyranyl ethers are removed under neutral conditions using Ag(I) or Hg(II) (Cohen and Steele, 1966; Cruse et al., 1978). Photochemical deblocking can be used with photochemically cleavable protecting groups. Several protecting groups can be used for this method. The use of o-nitrobenzyl ether as a protecting group for the 2'-hydroxy functionality of ribonucleosides is known and demonstrated (Ohtsuka et al., 1978); it is removed by irradiation at 260 nm. Alkyl carbonate o-nitrobenzyl carbonate protecting groups are also removed by irradiation at pH 7 (Cama and Christensen, 1978). Enzymatic deblocking of the 3'-OH protecting group is also possible. T4 polynucleotide kinase has been shown to convert 3'-phosphate termini into 3'-hydroxy termini that can then be used as primers for DNA polymerase I (Henner et al., 1983). This 3'-phosphatase activity is used to remove the 3' protecting group of those dNTP analogs that contain phosphate as a protecting group.
[0122] Other reagents that can remove protecting groups from 3'-blocked nucleotides include, for example, phosphines (e.g., tris(hydroxymethyl)phosphine (THP)), which can, for example, remove azide-containing 3'-OH protecting groups from nucleotides (for this application of phosphines, see, for example, the description in WO2014139596, the entire contents of which are incorporated herein by reference). Other reagents that can remove protecting groups from 3'-blocked nucleotides also include, for example, the corresponding reagents described on pages 114-116 of WO2004 / 018497 for removing 3'-allyl, 3,4-dimethoxybenzyloxymethyl or fluoromethoxymethyl as 3'-OH protecting groups.
[0123] In an embodiment of the present invention, the label of the nucleotide is preferably removed together with the protecting group after detection.
[0124] In certain embodiments, the label may be incorporated into a protecting group, thereby allowing it to be removed along with the protecting group after the 3' blocked nucleotide has been incorporated into the nucleic acid strand.
[0125] In other embodiments, the label can utilize linking group and blocking group to be connected on nucleotide separately.Such label can for example be connected on the purine or pyrimidine base of nucleotide.In certain embodiments, the linking group used is cleavable.The use of cleavable linking group can ensure that the mark can be removed after detection, which avoids any signal interference with any labeled nucleotide of subsequent incorporation.In other embodiments, non-cleavable linking group can be used, because after labeled nucleotide is incorporated into nucleic acid chain, subsequent nucleotide is not required to be incorporated, therefore mark does not need to be removed from nucleotide.
[0126] In other embodiments, the label and / or linker group may have a size or structure sufficient to act as a barrier to the incorporation of other nucleotides into the polynucleotide chain (that is, the label itself may serve as a protecting group). The barrier may be due to steric hindrance, or may be due to a combination of size, charge, and structure.
[0127] Cleavable linking groups are well known in the art and conventional chemical methods can be used to attach the linking group to the nucleotide base and the label. The linking group can be attached to any position of the nucleotide base, provided that Watson-Crick base pairing can still be performed. For purine bases, it will be preferred if the linking group is attached through the 7 position of the purine or preferred deazapurine analog, through an 8-modified purine, through an N-6 modified adenine or an N-2 modified guanine. For pyrimidines, the connection is preferably connected through the 5 position on cytosine, thymine and uracil and the N-4 position on cytidine.
[0128] The use of the term "cleavable linking group" does not imply that the entire linking group needs to be removed (e.g., removed from a nucleotide base). When the label is attached to a base, the nucleoside cleavage site can be located at a position on the linking group that ensures that a portion of the linking group remains attached to the nucleotide base after cleavage.
[0129] Suitable linking groups include, but are not limited to, disulfide linking groups, acid-labile linking groups (including dialkoxybenzyl linking groups, Sieber linking groups, indole linking groups, tert-butyl Sieber linking groups), electrophilic cleavable linking groups, nucleophilic cleavable linking groups, photocleavable linking groups, linking groups that cleave under reducing conditions, oxidative conditions, safety-catch linking groups, and linking groups that cleave by an elimination mechanism. Suitable linking groups can be modified with standard chemical protecting groups, as disclosed in Greene & Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons. Other suitable cleavable linking groups for solid phase synthesis are disclosed by Guillier et al. (Chem. Rev. 100: 2092-2157, 2000).
[0130] The linking group can be cleaved by any suitable method, including contact with acid, base, nucleophile, electrophile, free radical, metal, reducing or oxidizing agent, light, temperature, enzyme, etc., and the following will exemplarily describe the suitable cleavage mode of various cleavable linking groups. Generally, the cleavable linking group can be cleaved under the same conditions as the protecting group, so that only one treatment is required to remove the label and the protecting group.
[0131] Electrophilic cleavage linking groups are typically cleaved by protons and include acid-sensitive cleavage. Suitable electrophilic cleavage linking groups include modified benzyl systems, such as trityl, p-hydrocarbyloxybenzyl esters and p-hydrocarbyloxybenzyl amides. Other suitable linking groups include tert-butyloxycarbonyl (Boc) groups and acetal systems. For the preparation of suitable linking molecules, it is also possible to consider using sulfur-philic metals such as nickel, silver or mercury in the cleavage of thioacetal or other sulfur-containing protecting groups. Nucleophilic cleavage linking groups include unstable groups in water (i.e., can be simply cleaved at alkaline pH values), such as esters, and groups that are unstable to non-aqueous nucleophiles. Fluoride ions can be used to cleave silicon-oxygen bonds in groups such as triisopropylsilane (TIPS) or tert-butyldimethylsilane (TBDMS). Photolytic linking groups are widely used in sugar chemistry. Preferably, the light required for activation cleavage does not affect other components in the modified nucleotides. For example, if a fluorophore is used as a label, preferably, the fluorophore absorbs light of a different wavelength from the light required for the cleavage linking molecule. Suitable linking groups include those based on O-nitrobenzyl compounds and nitroveratinyl compounds. Linking groups based on benzoin chemistry can also be used (Lee et al., J.Org.Chem.64:3454-3460,1999). A variety of linking groups that are sensitive to reduction cleavage are known. Catalytic hydrogenation based on palladium catalysts has been used to cleave benzyl and benzyloxycarbonyl groups. Disulfide bond reduction is also known in the art. Oxidation-based methods are well known in the art. These methods include oxidation of alkoxybenzyl and oxidation of sulfur and selenium linking groups. Using iodine solution (aqueous iodine) to cleave disulfides and other sulfur- or selenium-based linking groups is also within the scope of the present invention. Safety-catch linkers are those linking groups that are cleaved in two steps. In a preferred system, the first step is the generation of a reactive nucleophilic center, and the subsequent second step involves intramolecular cyclization, which leads to cleavage. For example, the levulinate ester linkage can be treated with hydrazine or photochemical methods to release the active amine, which is then cyclized to cleave esters elsewhere in the molecule (Burgess et al., J. Org. Chem. 62:5165-5168, 1997). Elimination reactions can also be used to cleave the linking group. Base-catalyzed elimination of groups such as fluorenylmethoxycarbonyl and cyanoethyl and palladium-catalyzed reduction elimination of allyl systems can be used.
[0132] In certain embodiments, the linker may comprise a spacer unit. The length of the linker is not critical, as long as the label is kept at a sufficient distance from the nucleotide so as not to interfere with the interaction between the nucleotide and the enzyme.
[0133] In certain embodiments, the linking group may consist of a functional group similar to the 3'-OH protecting group. This would require only a single treatment to remove the label and the protecting group. A particularly preferred linking group is an azide-containing linking group that can be cleaved by a phosphine.
[0134] As used herein, the reagent that can remove the label from the modified nucleotide depends largely on the label used. For example, in the case where the label is incorporated with a protecting group, the label is removed using the reagent for removing the protecting group as described above. Alternatively, when the label is connected to the base of the nucleotide via a cleavable linking group, the label is removed using the reagent for cleaving the linking group as described above. In a preferred embodiment, the same reagent is used to remove the label and the protecting group from the modified nucleotide, for example, in the case where the linking group is composed of a functional group similar to the 3'-OH protecting group.
[0135] Reagent test kit
[0136] The present invention also provides a kit for sequencing a polynucleotide, comprising:
[0137] (a) four compounds, wherein the four compounds are derivatives of nucleotides A, (T / U), C and G, respectively, and have base complementary pairing ability; and the hydroxyl group (-OH) at the 3' position of the ribose or deoxyribose of the four compounds is protected by a protecting group; and,
[0138] The first compound is linked to a first molecular label,
[0139] The second compound is linked to a second molecular label,
[0140] The third compound is connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and another part of the third compound is connected to the second molecular marker,
[0141] The fourth compound has no molecular marker attached; and
[0142] (b) Two different luciferases, the two luciferases can specifically bind to the first molecular marker and the second molecular marker, respectively.
[0143] In a specific embodiment, the molecular labels used to label the four compounds and the labels used to label the two luciferases are as defined above.
[0144] In certain preferred embodiments, the kit of the present invention further comprises: reagents and / or devices for extracting nucleic acid molecules from a sample; reagents for pre-treating nucleic acid molecules; a support for connecting the nucleic acid molecules to be sequenced; reagents for connecting the nucleic acid molecules to be sequenced to the support (e.g., covalently or non-covalently); primers for initiating nucleotide polymerization reactions; a polymerase for performing nucleotide polymerization reactions; one or more buffer solutions; one or more washing solutions; or any combination thereof.
[0145] In certain preferred embodiments, the kit of the present invention also comprises a reagent and / or device for extracting nucleic acid molecules from a sample. The method for extracting nucleic acid molecules from a sample is well known in the art. Therefore, various reagents and / or devices for extracting nucleic acid molecules can be configured in the kit of the present invention as required, such as reagents for crushing cells, reagents for precipitating DNA, reagents for washing DNA, reagents for dissolving DNA, reagents for precipitating RNA, reagents for washing RNA, reagents for dissolving RNA, reagents for removing proteins, reagents for removing DNA (e.g., when the target nucleic acid molecule is RNA), reagents for removing RNA (e.g., when the target nucleic acid molecule is DNA), and any combination thereof.
[0146] In some preferred embodiments, the kit of the present invention also comprises a reagent for pre-treating nucleic acid molecules. In the kit of the present invention, the reagent for pre-treating nucleic acid molecules is not subject to additional restrictions, and can be selected according to actual needs. The reagent for pre-treating nucleic acid molecules includes, for example, a reagent (such as DNA enzyme I) for nucleic acid molecule fragmentation, a reagent (such as DNA polymerase, such as T4 DNA polymerase, Pfu DNA polymerase, Klenow DNA polymerase) for polishing nucleic acid molecule ends, a connector molecule, a label molecule, a reagent (such as ligase, such as T4 DNA ligase) for connecting a connector molecule to a target nucleic acid molecule, a reagent (such as a DNA polymerase, such as T4 DNA ligase) for repairing nucleic acid nicks (such as, losing 3'-5' exonuclease activity but showing 5'-3' exonuclease activity), a reagent (such as, DNA polymerase, primer, dNTP) for amplifying nucleic acid molecules, a reagent (such as a chromatography column) for separating and purifying nucleic acid molecules, and any combination thereof.
[0147] In certain preferred embodiments, the kit of the present invention further comprises a support for connecting the nucleic acid molecule to be sequenced. The support may have any technical features described in detail above for the support and any combination thereof.
[0148] For example, in the present invention, the support can be made of various suitable materials. Such materials include, for example, inorganic substances, natural polymers, synthetic polymers, and any combination thereof. Specific examples include, but are not limited to, cellulose, cellulose derivatives (e.g., nitrocellulose), acrylic resins, glass, silica gel, polystyrene, gelatin, polyvinyl pyrrolidone, copolymers of vinyl and acrylamide, cross-linked polystyrenes such as divinylbenzene (see, for example, Merrifield Biochemistry 1964, 3, 1385-1390), polyacrylamide, latex, dextran, rubber, silicon, plastics, natural sponges, metal plastics, cross-linked dextran (e.g., Sephadex TM ), Sepharose TM ), and other supports known to those skilled in the art.
[0149] In certain preferred embodiments, the support for attaching the nucleic acid molecules to be sequenced may be a solid support comprising an inert substrate or matrix (e.g., a glass slide, polymer beads, etc.) that has been functionalized, for example, by applying an intermediate material containing reactive groups that allow covalent attachment of biomolecules such as polynucleotides. Examples of such supports include, but are not limited to, polyacrylamide hydrogels supported on an inert substrate such as glass, in particular polyacrylamide hydrogels described in WO 2005 / 065814 and US 2008 / 0280773, the contents of which are incorporated herein by reference in their entirety. In such embodiments, the biomolecules (e.g., polynucleotides) may be directly covalently attached to the intermediate material (e.g., hydrogel), while the intermediate material itself may be non-covalently attached to the substrate or matrix (e.g., a glass substrate). In certain preferred embodiments, the support is a glass or silicon wafer with a layer of avidin, amino, acrylamide silane, or aldehyde chemical groups modified on the surface.
[0150] In the present invention, the support or solid support is not limited to its size, shape and configuration. In some embodiments, the support or solid support is a planar structure, such as a slide, a chip, a microchip and / or an array. The surface of this type of support can be in the form of a planar layer. In some embodiments, the support or its surface is non-planar, such as the inner or outer surface of a tube or container. In some embodiments, the support or solid support includes a microsphere or a bead. In certain preferred embodiments, the support for connecting the nucleic acid molecule to be sequenced is an array of beads or holes.
[0151] In certain preferred embodiments, the kit of the present invention further comprises a reagent for connecting the nucleic acid molecule to be sequenced to a support (e.g., covalently or non-covalently). Such reagents include, for example, reagents for activating or modifying nucleic acid molecules (e.g., their 5' end), such as phosphoric acid, thiol, amine, carboxylic acid or aldehyde; reagents for activating or modifying the surface of the support, such as amino-alkoxysilanes (e.g., aminopropyltrimethoxysilane, aminopropyltriethoxysilane, 4-aminobutyltriethoxysilane, etc.); cross-linking agents, such as succinic anhydride, phenyl diisothiocyanate (Guo et al., 1994), maleic anhydride (Yang et al., 1998), 1-ethyl-3-(3-dimethoxysilane) ...Yang et al., 1998), 1-ethyl-3-(3-dimethoxysilane) ( methylaminopropyl)-carbodiimide hydrochloride (EDC), m-maleimidobenzoic acid-N-hydroxysuccinimide ester (MBS), N-succinimidyl [4-iodoacetyl] aminobenzoic acid (SIAB), 4-(N-maleimidomethyl) cyclohexane-1-carboxylic acid succinimide (SMCC), N-γ-maleimidobutyryloxy-succinimide ester (GMBS), 4-(p-maleimidophenyl) butyric acid succinimide (SMPB); and any combination thereof.
[0152] In certain preferred embodiments, the kit of the present invention also includes a primer for initiating nucleotide polymerization. In the present invention, the primer is not subject to additional restrictions, as long as it can specifically anneal to a region of the target nucleic acid molecule. In some exemplary embodiments, the length of the primer can be 5-50bp, such as 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50bp. In some exemplary embodiments, the primer may include naturally occurring or non-naturally occurring nucleotides. In some exemplary embodiments, the primer includes naturally occurring nucleotides or is composed of naturally occurring nucleotides. In some exemplary embodiments, the primer includes modified nucleotides, such as locked nucleic acid (LNA). In certain preferred embodiments, the primer includes a universal primer sequence.
[0153] In some preferred embodiments, the test kit of the present invention also comprises a polymerase for carrying out nucleotide polymerization reaction. In the present invention, various suitable polymerases can be used. In some exemplary embodiments, the polymerase can be used to synthesize new DNA chains (such as DNA polymerase) as a template with DNA. In some exemplary embodiments, the polymerase can be used to synthesize new DNA chains (such as reverse transcriptase) as a template with RNA. In some exemplary embodiments, the polymerase can be used to synthesize new RNA chains (such as RNA polymerase) as a template with DNA or RNA. Therefore, in some preferred embodiments, the polymerase is selected from DNA polymerase, RNA polymerase, and reverse transcriptase.
[0154] In certain preferred embodiments, the kit of the present invention further comprises one or more buffer solutions. Such buffers include, but are not limited to, buffer solutions for DNA enzyme I, buffer solutions for DNA polymerase, buffer solutions for ligase, buffer solutions for eluting nucleic acid molecules, buffer solutions for dissolving nucleic acid molecules, buffer solutions for carrying out nucleotide polymerization reactions (e.g., PCR), and buffer solutions for carrying out ligation reactions. The kit of the present invention may comprise any one or more of the above-mentioned buffer solutions.
[0155] In certain preferred embodiments, the kit of the present invention further comprises one or more washing solutions. Examples of such washing solutions include, but are not limited to, phosphate buffer, citrate buffer, Tris-HCl buffer, acetate buffer, carbonate buffer, etc. The kit of the present invention may comprise any one or more of the above-mentioned washing solutions.
[0156] Advantageous Effects of the Invention
[0157] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:
[0158] (1) The method of the present invention uses only two molecular markers to achieve labeling of four nucleotides, and achieves self-luminescence by using luciferase. Therefore, the sequencing device used in the sequencing method of the present invention does not need to be equipped with an excitation light source, nor does it need to adopt an additional design to filter the background generated by the laser light source. On the one hand, this greatly reduces the manufacturing cost of the sequencing device, which is conducive to the promotion and application of the sequencing device and the sequencing method; on the other hand, it significantly reduces the size of the sequencing device, making the sequencing device more lightweight and easy to carry.
[0159] (2) The 3'-terminal hydroxyl group of the deoxyribonucleotide used in the sequencing method of the present invention is modified and blocked. During the sequencing process, only one deoxyribonucleotide can be synthesized in each reaction, ensuring that only one deoxyribonucleotide is combined in each reaction, thereby improving the accuracy of sequencing.
[0160] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes may be made to the details according to all the teachings disclosed, and these changes are within the scope of protection of the present invention. The full scope of the present invention is given by the attached claims and any equivalents thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0161] Figure 1 : Schematic diagram of the coupling procedure of antibody and Nluc. The enzyme in the figure refers to Nluc, and the antibody in the figure refers to digoxin antibody. Example
[0162] Example 1
[0163] 1. Sequencing library construction
[0164] (1) Design the following DNA sequence: (SEQ ID NO: 1), for the convenience of library construction, oligo sequences (bold font) were added to both ends of the sequence, and the BGISEQ-500 adapter sequence (shaded part) was inserted in the middle part, and the italic bold part is the first 10bp base of the sequence to be tested. The above sequence was synthesized by GenScript Biotech, and the synthesized sequence was inserted into the pUC57 vector for unlimited use of the sequence and transformed into E. coli bacteria.
[0165] (2) Culture an appropriate amount of E. coli bacteria containing a known library, extract plasmids, design the following pair of primers: GATATCTGCAGGCAT (primer 1, SEQ ID NO: 2), GATATCACAGGCTGA (primer 2, SEQ ID NO: 3), amplify the known sequence according to the following system (Table 1) and process (Table 2), and purify the PCR product using magnetic beads. Add split oligo (ATGCCTGCAGATATCGATATCACAGGCTGA, SEQ ID NO: 4) to the purified PCR product and perform circularization library construction according to the BGISEQ-500SE50 circularization library construction kit (MGI) and process, and set aside;
[0166] Table 1 (Enzymes from BGI)
[0167]
[0168]
[0169] Table 2:
[0170]
[0171] 2. Amplification of library sequences
[0172] Purchase a 96-well plate coated with Streptavidin from Thermo Fisher, incubate 100 μl of 1 μM 5'-end biotin-modified primer GCCATGTCGTTCTGTGAGCCAAGG (SEQ ID NO: 5) in one well at room temperature for 30 min, remove the reaction liquid, add 6 ng of the library constructed in Section 1 above and 20 μl of DNB preparation buffer I in the BGISEQ-500 kit (MGI), perform primer hybridization with the above biotin-modified primer at 60°C for 5 min, add 40 μl of DNB polymerase I and 4 μl of DNB polymerase II in the BGISEQ-500 sequencing kit (MGI), react at 30°C for 60 min, heat to 65°C to terminate the reaction, and carefully remove the reaction liquid. Add 100 μl of 5 μM sequencing primer GCTCAGAACGACATGGCTACGATCCGACTT (SEQ ID NO: 6), hybridize at room temperature for 30 min, and carefully remove the reaction liquid;
[0173] 3. Sequencing
[0174] (1) Acme Bioscience outsourced the synthesis of the following four dNTPs:
[0175]
[0176]
[0177] (2) Preparation of two luciferases:
[0178] a. SA-Gluc (purchased from adivity)
[0179] b. Antibody (purchased from Abcam) coupled with Nluc (purchased from Avidity) to prepare Ab-Nluc
[0180] Purchase the thermoprotein coupling kit and follow the instructions and Figure 1 The indicated procedure was used for conjugation of antibodies to Nluc.
[0181] (3) Reagent preparation:
[0182] Prepare other reagents required for sequencing reaction
[0183] Polymerization reaction solution: 50mM Tris-Hcl, 50mM NaCl, 10mM (NH4)2SO4, 0.02mg / ml polymerase BG9 (BGI), 3mM MgSO4, 1mM EDTA, 1μM of each of the above four dNTPs;
[0184] Elution buffer: 5XSSC, Tween20 0.05%;
[0185] Enzyme binding reaction solution: dilute the above two enzymes into TBST buffer, and the final concentration of the two enzymes is 2 μg / ml each;
[0186] Substrate 1 reaction solution: prepare 50mM tris-HCl 0.5mM Nacl buffer and dilute 50X Coelenterazine (nanolight) to 1X;
[0187] Substrate 2 reaction solution: prepare 50mM tris-HCl 0.5mM Nacl buffer and dilute 50XNLuc FLASHSubstrate (nanolight) to 1X;
[0188] Excision buffer: 20 mM THPP, 0.5 M NaCl, 50 mM Tris-HCl, pH 9.0, 0.05% tween20;
[0189] (4) Sequencing reaction:
[0190] Sequencing process:
[0191] a. Polymerization: Add 100 μl of polymerase reaction solution to the well of the amplified library, raise the temperature of the microplate reader to 55°C, react for 3 minutes, allow the four dNTPs to polymerize onto the amplified library, carefully remove the reaction solution, add 100 μl of elution reaction solution, gently blow several times to remove the elution reaction solution;
[0192] b. Luciferase binding: Add 100 μl enzyme binding reaction solution and incubate at 35°C for 30 min to allow SA-gluc to bind to the derivatives of dCTP and dATP labeled with biotin, and Ab-Nluc to bind to the derivatives of dCTP and dTTP labeled with digoxin. Remove the reaction solution, add the eluent, and blow gently.
[0193] After a few beatings, remove the wash solution;
[0194] c. Enzyme 1 signal detection: Set appropriate parameters of the microplate reader, add substrate 1 reaction solution, perform enzyme 1 signal detection, and record the highest signal value;
[0195] d. Enzyme 2 signal detection: remove substrate reaction solution 1, set appropriate parameters of the microplate reader, add substrate 2 reaction solution, perform enzyme 2 signal detection, and record the highest signal value;
[0196] e. Excision; remove the substrate 2 reaction solution, add 200 μl elution buffer, gently blow several times, remove the elution buffer, add 100 μl excision reaction solution, react at 55°C for 3 minutes, remove the excision reaction solution; add 200 μl elution buffer for washing, repeat washing three times;
[0197] f. Repeat steps ae to perform the next cycle of sequencing; a total of 10 bp sequencing is performed;
[0198] (5) Sequencing results
[0199] a. The signal values of the two luminescences are as follows:
[0200] Substrate 1 signal (W) Substrate 2 signal (W) cycle1 0.1 210 cycle2 188 0.12 cycle3 173 169 cycle4 206 0.11 cycle5 198 0.13 cycle6 176 171 cycle7 0.13 186 cycle8 203 0.15 cycle9 166 159 cycle10 0.12 0.16
[0201] b. Analysis of sequencing results:
[0202] According to the luminescent signal value, cycle 1 and cycle 7 only have signals when substrate 2 is introduced. It can be inferred that these two cycles are polymerized with biotin-dTTP, and the first base and the seventh base of the library to be tested are T bases;
[0203] Cycle 2, cycle 4, cycle 5 and cycle 8 only have signals when substrate 1 is introduced. It can be inferred that these four cycles polymerize digoxin-dATP, so the second, fourth, fifth and eighth bases of the library to be tested are A bases;
[0204] After the introduction of substrate 1 and substrate 2, signals were generated in cycle 3, cycle 6 and cycle 9. It can be inferred that biotin-digoxin-dCTP was polymerized in these two cycles, so the third, sixth and ninth bases of the library to be tested are C bases.
[0205] Cycle 10 did not emit light when the substrate was introduced twice, which shows that this cycle polymerized coldG, and therefore the tenth base of this library is G base.
[0206] In summary, the first 10 bases of the tested sequence are: TACAACTACG (SEQ ID NO: 7), which matches 100% with the first 10 bp base sequence TACAACTACG (SEQ ID NO: 7) of the library to be tested.
[0207] Example 2
[0208] The construction of sequencing library and library sequence amplification are shown in Example 1.
[0209] Sequencing:
[0210] (1) Four dNTPs as shown in Example 1
[0211] (2) Preparation of luciferase and related proteins
[0212] a. SA-Gluc (purchased from adivity)
[0213] b. Antibody (purchased from Abcam) was labeled with a biotin tag according to the instruction manual of Thermo Fisher NHS-ss-biotin to prepare antibody-ss-biotin.
[0214] (3) Reagent preparation
[0215] Prepare other reagents required for sequencing reaction
[0216] Polymerization reaction solution: 50mM Tris-Hcl, 50mM NaCl, 10mM (NH4)2SO4, 0.02mg / ml polymerase BG9 (BGI), 3mM MgSO4, 1mM EDTA, 1μM of each of the above four dNTPs;
[0217] Elution buffer: 5XSSC, Tween20 0.05%;
[0218] Enzyme binding reaction solution: dilute the above two proteins SA-Gluc and antibody-ss-biotin into TBST buffer, and the final concentration of the two proteins is 2 μg / ml respectively;
[0219] Substrate reaction solution: prepare 50mM Tris-HCl 0.5mM NaCl buffer and dilute 50X Coelenterazine (nanolight) to 1X;
[0220] Enzyme inactivation buffer: 5 mM DTT, 50 mM Tris-HCl, pH 9.0;
[0221] Excision buffer: 20 mM THPP, 50 mM Tris-HCl, pH 9.0, 0.5 M NaCl, 0.05% tween 20;
[0222] (4) Sequencing reaction
[0223] a. Polymerization: Add 100 μl of polymerase reaction solution to the well of the amplified library, raise the temperature of the microplate reader to 55°C, react for 3 minutes, allow the four dNTPs to polymerize onto the amplified library, carefully remove the reaction solution, add 100 μl of elution reaction solution, gently blow several times to remove the elution reaction solution;
[0224] b. Luciferase binding: Add 100 μl of luciferase SA-Gluc binding reaction solution, incubate at 35°C for 30 minutes to allow SA-gluc to bind to the biotin-labeled dCTP and dATP derivatives, remove the reaction solution, add the eluent, gently pipette several times, and then remove the eluent;
[0225] c. First signal detection: Set appropriate parameters of the microplate reader, add substrate reaction solution, perform signal detection, and record the highest signal value;
[0226] d. Enzyme inactivation: remove the substrate reaction solution, add enzyme inactivation buffer, incubate at 35°C for 10 min, remove the reaction solution, and then add elution buffer for elution;
[0227] e. Second luciferase binding: add antibody-SS-biotin reaction solution, incubate at 35°C for 30 minutes, allow antibody-ss-biotin to bind to digoxin-labeled dCTP and dTTP derivatives, remove the reaction solution, add elution buffer, gently blow several times, remove the elution solution, add 100 μl SA-Gluc binding reaction solution, incubate at 35°C for 30 minutes, remove the reaction solution, add elution buffer, and remove the elution buffer after elution;
[0228] f. Second signal detection: Set appropriate parameters of the microplate reader, add substrate reaction solution, perform signal detection, and record the highest signal value;
[0229] g. Excision; remove the substrate 2 reaction solution, add 200 μl elution buffer, gently blow several times, remove the elution buffer, add 100 μl excision reaction solution, react at 55°C for 3 minutes, remove the excision reaction solution; add 200 μl elution buffer to wash, repeat washing three times;
[0230] h. Repeat steps ag to proceed to the next cycle of sequencing; a total of 10 bp sequencing is performed.
[0231] (5) Sequencing results
[0232] a.10bp signal detection is as follows:
[0233] First detection (w) Second test (w) cycle1 0.6 223 cycle2 312 0.7 cycle3 278 327 cycle4 254 0.3 cycle5 239 0.4 cycle6 243 275 cycle7 0.27 228 cycle8 267 0.5 cycle9 263 279 cycle10 0.7 0.6
[0234] b. Analysis of sequencing results:
[0235] Cycle 1 and cycle 7 only have signal values in the second time. It is speculated that biotin-dTTP is polymerized in these two cycles, so the first and seventh bases of the library to be tested are T;
[0236] Cycle 2, cycle 4, cycle 5 and cycle 8 only have signals in the first detection. It can be inferred that these four cycles are polymerized digoxin-dATP, so the second, fourth, fifth and eighth bases of the library to be tested are A bases;
[0237] Cycle3, cycle6 and cycle9 all produced signals during the first and second detections, which indicates that biotin-digoxin-dCTP was polymerized in these two cycles, so the third, sixth and ninth bases of the library to be tested are C bases.
[0238] Cycle 10 did not emit light during both signal detections, which indicates that this cycle polymerized coldG, and therefore the tenth base of this library is a G base.
[0239] In summary, the first 10 bases of the tested sequence are: TACAACTACG (SEQ ID NO: 7), which matches 100% with the first 10 bp base sequence TACAACTACG (SEQ ID NO: 7) of the library to be tested.
Claims
1. A sequencing device, comprising: A solid support, wherein one or more nucleic acid molecules to be detected are fixed on the surface of the solid support; A kit comprising: a polymerase and four nucleotide derivatives, wherein the four nucleotide derivatives have base complementary pairing ability, and the hydroxyl groups at the 3' position of the ribose or deoxyribose of the four compounds are protected by a protecting group; A signal detection unit, used to detect the fluorescent signal generated by the nucleotide polymerization reaction; and An analysis unit, used for analyzing the fluorescence signal and outputting nucleic acid sequence information; Wherein, the sequencing device does not include an excitation light source; Preferably, the sequencing device is a single-channel sequencing device.
2. The sequencing device according to claim 1, wherein: The kit further comprises luciferase and a substrate.
3. The sequencing device according to claim 1, wherein: The kit further comprises nucleotide polymerization primers and one or more buffer solutions.
4. The sequencing device according to claim 2, wherein: The four compounds are derivatives of nucleotides A, T / U, C and G, respectively, and The first compound is linked to a first molecular label, The second compound is linked to a second molecular label, The third compound is connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and another part of the third compound is connected to the second molecular marker, The fourth compound has no molecular tag attached.
5. The sequencing device according to claim 4, wherein: There are two kinds of luciferases, and the two luciferases can specifically bind to the first molecular marker and the second molecular marker respectively, and the two luciferases are the same or different.
6. The sequencing device according to any one of claims 2 to 5, wherein: The four nucleotide derivatives undergo base complementary pairing reaction with the nucleic acid molecules to be detected on the surface of the solid support, and a fluorescent signal is generated by the reaction of luciferase and substrate, and the fluorescent signal represents the type of nucleotides that undergo complementary pairing. 7 . The sequencing device according to claim 1 , wherein the signal detection unit collects fluorescent signals in the absence of an excitation light source, and the signal detection device is a semiconductor chip.
8. The sequencing device according to any one of claims 1 to 7, wherein the excitation light source is a laser and an optical path system. 9 . The sequencing device according to claim 1 , wherein the single channel is a single-color fluorescent signal, and the single-color fluorescent signal is a fluorescent signal generated by a reaction between luciferase and a substrate.
10. A method for sequencing a nucleic acid molecule, comprising the following steps: (1) providing a nucleic acid molecule to be sequenced fixed on a support, or fixing the nucleic acid molecule to be sequenced on a support; (2) adding a primer for initiating nucleotide polymerization reaction, a polymerase for carrying out nucleotide polymerization reaction, and four compounds to form a reaction system containing a solution phase and a solid phase; wherein the four compounds are derivatives of nucleotides A, T / U, C, and G, respectively, and have base complementary pairing capabilities; and the hydroxyl group at the 3' position of the ribose or deoxyribose of the four compounds is protected by a protecting group; (3) annealing the primer to the nucleic acid molecule to be sequenced, wherein the primer serves as the initial growing nucleic acid chain and forms a duplex fixed on the support together with the nucleic acid molecule to be sequenced; (4) performing nucleotide polymerization using a polymerase under conditions that allow the polymerase to perform nucleotide polymerization, thereby incorporating one of the four compounds into the 3' end of the growing nucleic acid chain; (5) detecting the fluorescent signal generated by the nucleotide polymerization reaction; and (6) analyzing the fluorescence signal and outputting the nucleic acid sequence information; in, The sequencing method does not require an excitation light source; Preferably, the sequencing method is a single-channel sequencing method.
11. The sequencing method according to claim 10, wherein in step (2), the four compounds are: The first compound is linked to a first molecular label, The second compound is linked to a second molecular label, The third compound is connected to the first molecular marker and the second molecular marker, or part of the third compound is connected to the first molecular marker and another part of the third compound is connected to the second molecular marker, The fourth compound had no molecular marker attached; The first molecular marker and the second molecular marker are different.
12. The sequencing method according to claim 11, wherein in step (5), The duplex in the previous step is contacted with a luciferase or two different luciferases and subjected to a binding reaction, wherein the one luciferase or the two luciferases can specifically bind to the first molecular marker and the second molecular marker, and then the luciferase is allowed to undergo a fluorescence reaction in the presence of a substrate, and the emitted fluorescence signal is detected; Preferably, the duplex is contacted with two different luciferases in a one-step reaction and subjected to a binding reaction.
13. The sequencing method according to any one of claims 10 to 12, further comprising the following steps: (7) Removal of molecular labels and 3'-OH protecting groups of each nucleotide.
14. The method according to any one of claims 10 to 13, further comprising the steps of: (8) Repeat steps (4)-(6) or (4)-(7) one or more times to obtain the sequence information of the nucleic acid molecule.
15. The sequencing method according to any one of claims 1 to 14, wherein: The support is a plane or microbeads.
16. The sequencing method according to any one of claims 1 to 14, wherein: The support is glass, ceramic, silicon or plastic.
17. The sequencing method according to any one of claims 1 to 14, wherein: The support is a flat glass surface or a silicon surface.
18. The sequencing method according to any one of claims 1 to 14, wherein: The support is a glass slide or a silicon wafer.
19. The sequencing method according to any one of claims 1 to 14, wherein: The support is a glass slide or silicon slide with a layer of avidin, amino, acrylamide silane or aldehyde chemical group modified on the surface.
20. The sequencing method according to any one of claims 1 to 14, wherein: The support is silicon dioxide.
21. The sequencing method according to any one of claims 1 to 14, wherein the first molecular marker and the second molecular marker are selected from biotin, digoxigenin, N3G or FITC, and the first luciferase and the second luciferase are labeled with streptavidin, digoxigenin antibody, N3G antibody or FITC antibody, respectively.
22. The sequencing method according to any one of claims 1 to 14, wherein: The four compounds are shown in the following formula I, formula II, formula III and formula IV:
